"Recurrence Even After 20 Years": The Final Puzzle in Curing Breast Cancer

■ Park In-hye, Professor of Oncology at Korea University Guro Hospital Breast Cancer Tops Female Cancers, Threatening Women in Their 40s and 50s Early-Stage Breast Cancer 5-Year Survival Tops 90%, but Recurrence Risk Remains High "Late Recurrence" Common Beyond 5 Years, with Survival Plummeting upon Distant Metastasis Combining Hormone Therapy with Targeted Treatment After Surgery Lowers Recurrence Risk Aggressive Anti-Recurrence Treatment Needed, but High Drug Costs Pose a Hurdle

Culture|
|
By Ahn Kyung-jin
|

Content not available. Please visit the original article.

#BreastCancer#CancerRecurrence#CDK46Inhibitor#WomensHealth#KoreaHealthcare#Oncology#MedicalInsight

Original reporting by Ahn Kyung-jin for Seoul Economic Daily.

AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.

View Korean originalTranslation Policy
AI PRISM cover art

🎧Listen to AI PRISM·AI PRISM

Real Estate: Dongtan Hits Record Weekly Gain, Seoul Jeonse Six Times 2025's Pace | June 05 2026

00:0004:11
← Back to Home

AI KEY

Preview
Korean Corporate Intelligence HubKOSPI · KOSDAQ · 12 sectors

A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.

Open in full screen

Korea Chaebol Tree

Preview
Families Behind the GroupsKFTC May 2026 · DART filings

An English-first interactive map of Samsung, SK, Hyundai, LG and Lotte — built for foreign investors, correspondents and analysts. Korea translates companies into English. We translate the families behind them.

Open in full screen

SIGNAL

Pre-register
English Edition · Capital MarketsM&A · IPO · PE · Fund Flows

Pre-register for SIGNAL English Edition — a premium subscription bringing Korean capital markets coverage (M&A, IPOs, private equity, fund flows) to global institutional investors. First access to the 50% introductory rate.

Open in full screen